SNSE Projected Dividend Yield
Sensei Biotherapeutics Inc ( NASDAQ : SNSE )Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated Biologics platform, Co. is developing therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals in the tumor microenvironment. Co.'s product candidates: SNS-101, which is Co.'s monoclonal antibody targeting the immune checkpoint V-domain Ig suppressor of T-cell activation; SNS-102, which is Co.'s monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4; and SNS-103, which is Co.'s monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1. 20 YEAR PERFORMANCE RESULTS |
SNSE Dividend History Detail SNSE Dividend News SNSE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |